Contraindications for Pantoprazole
Pantoprazole is contraindicated in patients with known hypersensitivity to any component of the formulation or any substituted benzimidazole, and in patients receiving rilpivirine-containing products. 1
Absolute Contraindications
1. Hypersensitivity Reactions
Pantoprazole must not be used in patients with documented hypersensitivity to:
- Any component of the pantoprazole formulation
- Any substituted benzimidazole compounds (this includes other PPIs)
Hypersensitivity reactions can manifest as:
- Anaphylaxis or anaphylactic shock
- Angioedema
- Bronchospasm
- Acute tubulointerstitial nephritis
- Urticaria 1
2. Concomitant Use with Rilpivirine
Proton pump inhibitors, including pantoprazole, are absolutely contraindicated in patients taking rilpivirine-containing antiretroviral products. 1 This is because PPIs significantly decrease rilpivirine exposure, which can reduce antiviral efficacy and promote development of drug resistance.
Important Drug Interactions Requiring Caution (Not Absolute Contraindications)
While not absolute contraindications, the following warrant careful consideration:
Atazanavir
- Avoid concomitant use or follow specific dosing guidance per atazanavir prescribing information
- PPIs decrease atazanavir exposure, potentially reducing antiviral effect 1
Nelfinavir
- Avoid concomitant use with pantoprazole 1
Warfarin
- Monitor INR and prothrombin time closely
- Dose adjustment of warfarin may be needed
- Increased risk of abnormal bleeding 1
High-Dose Methotrexate
- Consider temporary withdrawal of pantoprazole in patients receiving high-dose methotrexate
- PPIs may elevate and prolong methotrexate serum concentrations, leading to toxicity 1
Clinical Context: Pantoprazole vs. Other PPIs
Pantoprazole has a notably favorable drug interaction profile compared to other PPIs. Unlike omeprazole and esomeprazole, pantoprazole does not significantly inhibit CYP2C19 2, 3. This makes it a preferred choice when clopidogrel is co-administered, as pantoprazole was not associated with recurrent MI in patients receiving clopidogrel 2, 3. The 2016 ACC/AHA guidelines specifically recommend non-cytochrome P450 2C19-interfering PPIs (pantoprazole, dexlansoprazole) over omeprazole or esomeprazole in patients requiring both PPI and clopidogrel therapy 4.
Common Pitfalls to Avoid
- Do not confuse relative contraindications with absolute contraindications: Only hypersensitivity and rilpivirine co-administration are absolute contraindications
- Do not assume all PPIs have the same interaction profile: Pantoprazole has fewer CYP2C19-mediated interactions than omeprazole or esomeprazole
- Do not overlook antiretroviral interactions: Always check for rilpivirine, atazanavir, or nelfinavir before prescribing pantoprazole